These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22123335)

  • 1. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
    Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
    Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
    Blagden SP; Molife LR; Seebaran A; Payne M; Reid AH; Protheroe AS; Vasist LS; Williams DD; Bowen C; Kathman SJ; Hodge JP; Dar MM; de Bono JS; Middleton MR
    Br J Cancer; 2008 Mar; 98(5):894-9. PubMed ID: 18319713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
    Souid AK; Dubowy RL; Ingle AM; Conlan MG; Sun J; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2010 Dec; 55(7):1323-8. PubMed ID: 20712019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
    Lee CW; Bélanger K; Rao SC; Petrella TM; Tozer RG; Wood L; Savage KJ; Eisenhauer EA; Synold TW; Wainman N; Seymour L
    Invest New Drugs; 2008 Jun; 26(3):249-55. PubMed ID: 17962907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
    Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
    Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
    Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
    Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of edatrexate in advanced breast and other cancers.
    Kuriakose P; Gandara DR; Perez EA
    Cancer Invest; 2002; 20(4):473-9. PubMed ID: 12094542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    Infante JR; Weiss GJ; Jones S; Tibes R; Bauer TM; Bendell JC; Hinson JM; Von Hoff DD; Burris HA; Orlemans EO; Ramanathan RK
    Eur J Cancer; 2014 Nov; 50(17):2897-904. PubMed ID: 25262379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
    Villalona-Calero MA; Eckhardt SG; Weiss G; Hidalgo M; Beijnen JH; van Kesteren C; Rosing H; Campbell E; Kraynak M; Lopez-Lazaro L; Guzman C; Von Hoff DD; Jimeno J; Rowinsky EK
    Clin Cancer Res; 2002 Jan; 8(1):75-85. PubMed ID: 11801542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
    J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.